Pharmacokinetics and serum bactericidal activity of vancomycin alone and in combination with ceftazidime in healthy volunteers. 1988

M Boeckh, and H Lode, and K Borner, and G Höffken, and J Wagner, and P Koeppe
Medical Department, Klinikum Steglitz, Freie Universität Berlin, Federal Republic of Germany.

The pharmacokinetics and serum bactericidal activity of vancomycin alone and in combination with ceftazidime were investigated in 10 healthy volunteers. The pharmacokinetic parameters showed no significant differences (P less than 0.05) between single and combined administration. No antagonistic effects were observed in serum bactericidal activity with the combination against 20 gram-positive and 20 gram-negative locally isolated bacteria. A titer of greater than or equal to 1:8 was generated by the combination against all test strains except enterococci. Seven of ten volunteers developed a typical "red man's syndrome" during the administration of 1.0 g of vancomycin.

UI MeSH Term Description Entries
D007262 Infusions, Intravenous The long-term (minutes to hours) administration of a fluid into the vein through venipuncture, either by letting the fluid flow by gravity or by pumping it. Drip Infusions,Intravenous Drip,Intravenous Infusions,Drip Infusion,Drip, Intravenous,Infusion, Drip,Infusion, Intravenous,Infusions, Drip,Intravenous Infusion
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D002442 Ceftazidime Semisynthetic, broad-spectrum antibacterial derived from CEPHALORIDINE and used especially for Pseudomonas and other gram-negative infections in debilitated patients. Ceftazidime Anhydrous,Ceftazidime Pentahydrate,Fortaz,Fortum,GR-20263,LY-139381,Pyridinium, 1-((7-(((2-amino-4-thiazolyl)((1-carboxy-1-methylethoxy)imino)acetyl)amino)-2-carboxy-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-en-3-yl)methyl)-, inner salt, pentahydrate, (6R-(6alpha,7beta(Z)))-,Tazidime,GR 20263,GR20263,LY 139381,LY139381
D004338 Drug Combinations Single preparations containing two or more active agents, for the purpose of their concurrent administration as a fixed dose mixture. Drug Combination,Combination, Drug,Combinations, Drug
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D001419 Bacteria One of the three domains of life (the others being Eukarya and ARCHAEA), also called Eubacteria. They are unicellular prokaryotic microorganisms which generally possess rigid cell walls, multiply by cell division, and exhibit three principal forms: round or coccal, rodlike or bacillary, and spiral or spirochetal. Bacteria can be classified by their response to OXYGEN: aerobic, anaerobic, or facultatively anaerobic; by the mode by which they obtain their energy: chemotrophy (via chemical reaction) or PHOTOTROPHY (via light reaction); for chemotrophs by their source of chemical energy: CHEMOLITHOTROPHY (from inorganic compounds) or chemoorganotrophy (from organic compounds); and by their source for CARBON; NITROGEN; etc.; HETEROTROPHY (from organic sources) or AUTOTROPHY (from CARBON DIOXIDE). They can also be classified by whether or not they stain (based on the structure of their CELL WALLS) with CRYSTAL VIOLET dye: gram-negative or gram-positive. Eubacteria
D014640 Vancomycin Antibacterial obtained from Streptomyces orientalis. It is a glycopeptide related to RISTOCETIN that inhibits bacterial cell wall assembly and is toxic to kidneys and the inner ear. AB-Vancomycin,Diatracin,VANCO-cell,Vanco Azupharma,Vanco-saar,Vancocin,Vancocin HCl,Vancocine,Vancomicina Abbott,Vancomicina Chiesi,Vancomicina Combino Phar,Vancomicina Norman,Vancomycin Hexal,Vancomycin Hydrochloride,Vancomycin Lilly,Vancomycin Phosphate (1:2),Vancomycin Phosphate (1:2), Decahydrate,Vancomycin Sulfate,Vancomycin-ratiopharm,Vancomycine Dakota,Hydrochloride, Vancomycin,Sulfate, Vancomycin

Related Publications

M Boeckh, and H Lode, and K Borner, and G Höffken, and J Wagner, and P Koeppe
November 1991, Antimicrobial agents and chemotherapy,
M Boeckh, and H Lode, and K Borner, and G Höffken, and J Wagner, and P Koeppe
December 1986, Antimicrobial agents and chemotherapy,
M Boeckh, and H Lode, and K Borner, and G Höffken, and J Wagner, and P Koeppe
March 2004, Antimicrobial agents and chemotherapy,
M Boeckh, and H Lode, and K Borner, and G Höffken, and J Wagner, and P Koeppe
January 1988, The Journal of antimicrobial chemotherapy,
M Boeckh, and H Lode, and K Borner, and G Höffken, and J Wagner, and P Koeppe
July 2003, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases,
M Boeckh, and H Lode, and K Borner, and G Höffken, and J Wagner, and P Koeppe
February 1986, Antimicrobial agents and chemotherapy,
M Boeckh, and H Lode, and K Borner, and G Höffken, and J Wagner, and P Koeppe
March 1983, Antimicrobial agents and chemotherapy,
M Boeckh, and H Lode, and K Borner, and G Höffken, and J Wagner, and P Koeppe
January 1994, The Journal of antimicrobial chemotherapy,
M Boeckh, and H Lode, and K Borner, and G Höffken, and J Wagner, and P Koeppe
March 1988, Antimicrobial agents and chemotherapy,
M Boeckh, and H Lode, and K Borner, and G Höffken, and J Wagner, and P Koeppe
June 2014, The American journal of tropical medicine and hygiene,
Copied contents to your clipboard!